Loading...
•
Dec 31, 2024
PROCEPT BioRobotics Q4 2024 Earnings Report
PROCEPT BioRobotics reported strong revenue growth driven by increased system sales and consumables.
Key Takeaways
PROCEPT BioRobotics reported revenue of $68.2 million for Q4 2024, a 57% increase year-over-year. The company recorded a net loss of $18.9 million, improving from a loss of $27.5 million in the prior year period. Operating expenses increased due to commercial expansion and higher general and administrative costs. Gross margin improved to 64% from 49% in the prior year period.
Revenue increased 57% to $68.2 million.
Net loss narrowed to $18.9 million from $27.5 million.
Gross margin improved to 64% from 49%.
U.S. system revenue increased 67% year-over-year.
PROCEPT BioRobotics
PROCEPT BioRobotics
PROCEPT BioRobotics Revenue by Segment
PROCEPT BioRobotics Revenue by Geographic Location
Revenue by Segment
U.S. System Sales & Rentals Revenue
CapyFin.comU.S. Handpieces & Consumables Revenue
CapyFin.comInternational System Sales & Rentals Revenue
CapyFin.comInternational Handpieces & Consumables Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
PROCEPT BioRobotics projects strong revenue growth for 2025 driven by system placements and consumables.
Positive Outlook
- 2025 revenue projected to grow 42% to $320 million.
- Gross margin expected to improve to 64.5%.
- Continued expansion of commercial operations.
- Increased focus on global market penetration.
- Launch of new robotic platform to drive growth.
Challenges Ahead
- Projected adjusted EBITDA loss of $35 million for 2025.
- Higher operating expenses anticipated.
- Dependence on consumable sales for revenue growth.
- Potential impact from supply chain issues.
- Increased competition in the surgical robotics space.
Revenue & Expenses
Visualization of income flow from segment revenue to net income